Skip to content

Author

Jia Luo

We have 4 of 20 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Sep 2026

Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.

BACKGROUND RAS mutations, as a group, are the most common oncogenic drivers of non-small-cell lung cancer (NSCLC), and they occur in approximately 30% of patients. Whether daraxonrasib (RMC-6236) - an oral RAS(ON) multiselective, tri-complex inhibitor of guanosine triphosphate-bound mutant and wild-type RAS protein iso...

K. Arbour, S. Punekar, Jia Luo et al. · 1 citation
#artificial intelligence Review Oct 2026

OpenMTB-Audit: Exposing Over-Refusal and Clinical Expert Perspectives in LLM-Based Molecular Tumor Board Safety Evaluation

This work introduces OpenMTB-Audit, an open-source benchmark of 500 synthetic non-small cell lung cancer cases spanning five adversarial error categories and four safety labels, and developed MTB-AuditAgent, a deterministic seven-module framework separating evidence verification, missing-information detection, safety c...

Negin Ashrafi, Jia Luo, Stacey M. Frumm et al. · 0 citations
Review Sep 2026

Targeting KRAS-Mutant Lung Cancers.

KRAS biology, therapeutic advances, mechanisms of resistance, and emerging strategies that are reshaping the treatment landscape of KRAS-mutant NSCLC are comprehensively summarized.

E. Garbo, P. Scaparone, H. J. Hoe et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.